Cipla Limited
https://www.cipla.com/home
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cipla Limited
Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?
The US FDA’s observations at its radiopharma manufacturing facility in Canada could be a headwind for Jubilant Pharmova, but reorientation of US generics manufacturing is expected to boost profits. Scrip takes a look at the likely impact.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Lilly CEO: Affordable Generics And IP Support 'Not Incompatible Ideas'
Lilly’s CEO indicates that the long-standing IPR debate that has generally divided the developed and developing world is largely a “false narrative”. The executive also called for lowering regulatory barriers in India amid expectations of the potential debut of Zepbound/Mounjaro in the country next year.
Lilly CEO: Affordable Generics And IP Support 'Not Incompatible Ideas'
Lilly’s CEO indicates that the long-standing IPR debate that has generally divided the developed and developing world is largely a “false narrative.” The executive also called for lowering regulatory barriers in India amid expectations of the potential debut of Zepbound/Mounjaro in the country next year.
Company Information
- Industry
- Contract Research Organization-CRO
- Medical Devices
- Pharmaceuticals
-
Services
- Consulting Services
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Nutraceuticals
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Cipla Gulf FZ LLC
- Cipla Technologies LLC
- InvaGen Pharmaceuticals Inc.
- Mirren Pty, Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice